Acute Pericarditis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Acute Pericarditis Market Outlook

Thelansis’s “Acute Pericarditis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Pericarditis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Acute Pericarditis Overview

Acute pericarditis is a relatively common cause of chest pain, with approximately 5% of patients with nonischemic chest pain being diagnosed with acute pericarditis in the emergency department. Recurrent or relapsing pericarditis is common, is one of the most challenging complications of acute pericarditis, and may affect 10–50% of patients. It can have infectious or non-infectious causes and is characterized by a combination of signs (e.g., pericarp. dial rubs, electrocardiographic changes, and pericardial effusion), symptoms (primarily chest pain, but other symptoms such as dyspnea are possible), and usually elevation of markers of myocardial inflammation (i.e., protein C reactive). Simultaneous myocardial involvement is also attributed to about one-third of patients with acute pericarditis, and it is due to overlapping etiological agents for pericarditis and myocarditis. It is the first pericarditis attack, generally occurring with an acute onset of symptoms. It is characterized by chest pain, pericardial friction rub, and serial ECG changes. Chest pain is the cardinal symptom of pericarditis, usually precordial or retrosternal, with referral to the trapezius ridge, neck, left shoulder, or arm.

• Acute Pericarditis incidence cases vary from 325 to 340 per 100,000 population in the USA.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: